TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-06 |
2024-09 |
0.03 |
N/A |
N/A |
N/A |
2024-08-06 |
2024-06 |
-0.04 |
0.04 |
0.08 |
200.00% |
2024-05-01 |
2024-03 |
-0.03 |
-0.07 |
-0.04 |
-133.33% |
2024-02-28 |
2023-12 |
-0.12 |
-0.09 |
0.03 |
25.00% |
2023-11-01 |
2023-09 |
0.29 |
0.73 |
0.44 |
151.72% |
2023-08-01 |
2023-06 |
-0.26 |
-0.34 |
-0.08 |
-30.77% |
Date |
Firm |
Action |
From |
To |
2023-10-19 |
B. Riley Securities |
Upgrade |
Buy |
Buy |
2023-09-17 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-06 |
JP Morgan |
Upgrade |
Overweight |
Overweight |
2023-08-02 |
Goldman Sachs |
Upgrade |
Neutral |
Neutral |
2023-08-01 |
B. Riley Securities |
Upgrade |
Buy |
Buy |
2023-08-01 |
Goldman Sachs |
Upgrade |
Sell |
Neutral |
Date |
Name |
Relation |
Quantity |
Description |
2024-06-18 |
CHARNEY LAURENCE NEIL |
Director |
237.48K |
Stock Award(Grant) |
2024-06-18 |
ECHELARD YANN |
Director |
244.10K |
Stock Award(Grant) |
2024-06-18 |
HOBERMAN KENNETH |
Director |
264.94K |
Stock Award(Grant) |
2024-06-18 |
HUME DANIEL |
Director |
240.49K |
Stock Award(Grant) |
2020-06-21 |
KENNEDY WILLIAM JAMES |
Director |
109.63K |
Stock Award(Grant) |
2024-06-19 |
LONIAL SAGAR |
Director |
105.20K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
13.46M |
334.22M |
8.91% |
2023-06-29 |
Blackrock Inc. |
9.92M |
246.35M |
6.57% |
2023-06-29 |
Darwin Global Management, Ltd. |
9.28M |
230.48M |
6.15% |
2023-06-29 |
FMR, LLC |
6.08M |
151.05M |
4.03% |
2023-06-29 |
State Street Corporation |
5.63M |
139.80M |
3.73% |
2023-06-29 |
Wellington Management Group, LLP |
3.16M |
78.48M |
2.09% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
4.28M |
106.28M |
2.83% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
3.47M |
86.22M |
2.30% |
2023-08-30 |
iShares Russell 2000 ETF |
3.12M |
32.70M |
2.07% |
2023-07-30 |
Vanguard Specialized-Health Care Fund |
3.07M |
63.44M |
2.03% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
2.55M |
26.69M |
1.69% |
2023-06-29 |
Vanguard Small-Cap Growth Index Fund |
1.99M |
49.38M |
1.32% |
Split |
Date |
0.01778 : 1 |
2012-04-30 |
1 : 1 |
2011-07-19 |
0.02 : 1 |
2011-07-14 |